Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors
- 1 February 2003
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 25 (2) , 472-484
- https://doi.org/10.1016/s0149-2918(03)80090-5
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Clinical Pharmacokinetics and Pharmacodynamics of RepaglinideClinical Pharmacokinetics, 2002
- Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.Diabetes Care, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- GlimepirideDrugs, 1998
- Increase of lipoprotein (a) with troglitazoneThe Lancet, 1997
- Lipoprotein(a) and Diabetes: An updateDiabetes Care, 1993
- Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groupsDiabetes Care, 1993
- Determination of total serum insulin (IRI) in insulin-treated diabetic patientsDiabetologia, 1972
- THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUMJournal of Clinical Investigation, 1955